Paper24141007
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.
Giralt S and 17 others. Biol Blood Marrow Transplant, 2014. Cited by 329 papers, by iCite.
Cite this record
ConductScience Library. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Papers, record 24141007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24141007
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hematopoietic Stem Cell Mobilization | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Heterocyclic Compounds | Major topic |
| Hodgkin Disease | Major topic |
| Lymphoma, Non-Hodgkin | Major topic |
| Multiple Myeloma | Major topic |
| Benzylamines | |
| Cyclams | |
| Filgrastim | |
| Granulocyte Colony-Stimulating Factor | |
| Granulocyte-Macrophage Colony-Stimulating Factor | |
| Humans | |
| Polyethylene Glycols | |
| Recombinant Proteins | |
| Survival Analysis | |
| Transplantation, Autologous |
Source PubMed
Cited by171
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 329 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42920448 | Cytarabine-based mobilisation yields higher CD34+ cell counts than cyclophosphamide regardless of prior daratumumab exposure in multiple myeloma. | Front Oncol | 2026 | https://conductscience.org/library/papers/42920448 | PubMed |
| 42864656 | Plerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE). | J Clin Apher | 2026 | https://conductscience.org/library/papers/42864656 | PubMed |
| 42718461 | A two-phase low-dose ACD-A strategy overcomes hypocalcemia during peripheral blood stem cell collection: a randomized controlled study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42718461 | PubMed |
| 42565354 | Impact of Bone Marrow Involvement on the Success of Hematopoietic Stem Cell Mobilization in Patients With Lymphoma. | Cancer Med | 2026 | https://conductscience.org/library/papers/42565354 | PubMed |
| 42440648 | Non-cryopreserved Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma in a Resource-Limited Setting: Feasibility, Engraftment Kinetics, and Early Outcomes From Kashmir, India. | Cureus | 2026 | https://conductscience.org/library/papers/42440648 | PubMed |
| 42360011 | Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study. | Am J Hematol | 2026 | https://conductscience.org/library/papers/42360011 | PubMed |
| 42352409 | Stem Cell Mobilization and Autologous Transplantation Outcomes After First-Line R-DA-EPOCH in High-Risk DLBCL and HGBCL: A Single-Center Retrospective Study. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42352409 | PubMed |
| 42338514 | Febrile neutropenia adversely affects chemomobilization outcomes in patients with multiple myeloma and increases risk for post-transplant infection in those with lymphoma: real-world multicenter data. | Blood Sci | 2026 | https://conductscience.org/library/papers/42338514 | PubMed |
| 42123282 | Pre-Transplant Prognostic Nutritional Index Independently Predicts Progression-Free Survival After Autologous Stem Cell Transplantation in Lymphoma. | J Clin Med | 2026 | https://conductscience.org/library/papers/42123282 | PubMed |
| 41952627 | Cyp7b1-inhibiting azoles enhance hematopoietic stem and progenitor cell mobilization in normal and sickle cell disease mice. | Haematologica | 2026 | https://conductscience.org/library/papers/41952627 | PubMed |
| 41739202 | Superiority of high-dose cytarabine-based mobilisation over cyclophosphamide or plerixafor in primary CNS lymphoma. | Ann Hematol | 2026 | https://conductscience.org/library/papers/41739202 | PubMed |
| 41279189 | Cyp7b1-inhibiting azoles as novel enhancers of hematopoietic stem and progenitor cell mobilization. | bioRxiv | 2025 | https://conductscience.org/library/papers/41279189 | PubMed |
| 41128425 | Streamlining Apheresis: A Dual-Intervention Quality Improvement Initiative to Increase the Efficiency in Stem Cell Collection. | J Clin Apher | 2025 | https://conductscience.org/library/papers/41128425 | PubMed |
| 41084581 | Low Dose Cyclophospahamide is a Feasable Mobilization Regimen in the Covid-19 Era: A Single Center Study from Türkiye. | Indian J Hematol Blood Transfus | 2025 | https://conductscience.org/library/papers/41084581 | PubMed |
| 41077583 | Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. | J Hematol Oncol | 2025 | https://conductscience.org/library/papers/41077583 | PubMed |
| 40932993 | GroβT rapidly and reliably mobilizes primitive hematopoietic stem and progenitor cells in nonhuman primates. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/40932993 | PubMed |
| 40317777 | Cost-Effectiveness of Preemptive Plerixafor Versus Rescue Plerixafor for Mobilization and Collection of Hematopoietic Stem Cells in Patients With Multiple Myeloma and Lymphoma. | J Clin Apher | 2025 | https://conductscience.org/library/papers/40317777 | PubMed |
| 40281003 | Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma. | Sci Rep | 2025 | https://conductscience.org/library/papers/40281003 | PubMed |
| 40238028 | Clinical benefit loss in myeloma patients declining autologous stem cell transplantation: a real-world study. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40238028 | PubMed |
| 40232588 | Intra-apheresis Cycling to Improve the Clinical Efficacy of Peripheral Blood Stem Cell Donations. | Sports Med | 2025 | https://conductscience.org/library/papers/40232588 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24141007
GET https://conductscience.org/api/papers/v1/24141007/cited_by?page=2